- Biopharmaceutical company Palatin Technologies Inc's (NYSE: PTN) Q4 FY22, Vyleesi gross product sales to pharmacy distributors, reached $2.3 million, with net product revenue of $770,738. Gross product sales increased 91% Y/Y, and net product revenue increased 857%.
- The company posted an EPS loss of $(1.34), missing the consensus loss of $(0.81) but lower than the $(1.47) posted a year ago.
- Vyleesi: Gross product sales increased 79%, net product revenue increased 257%, and prescriptions dispensed increased 49% over the prior quarter.
- Total prescriptions dispensed increased 49% over the prior quarter and 54% compared to the comparable quarter in 2021.
- As of June 30, 2022, the company had cash and cash equivalents of $29.9 million.
- Update from Clinical Trials:
- PL9643 for dry eye disease (DED): The independent data monitoring committee (DMC) reviewed the data from the first 120 patients. Palatin plans to enroll up to an additional 230 patients for a final sample size of 350.
- The DMC identified no safety concerns. Topline data readout is expected in Q2 2023.
- PL8177 for ulcerative colitis (UC): Initiated patient recruitment in a Phase 2 oral formulation study. Interim assessment is expected in Q1 2023, with topline data expected in Q2 2023.
- Price Action: PTN shares are down 5.42% at $7.50 during the premarket session on the last check Thursday.
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Palatin Technologies Shares Drop After Wider Than Expected Quarterly Loss
Published 22/09/2022, 14:22
Palatin Technologies Shares Drop After Wider Than Expected Quarterly Loss
Latest comments
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.